EPRX Eupraxia Pharmaceuticals Inc.
Price Chart
Executive Summary
Eupraxia Pharmaceuticals reported its Q4 2025 financial results, posting a wider net loss of $16.7 million compared to $7.5 million in the same quarter last year, driven by increased R&D and administrative costs. The company bolstered its cash position to $80.5 million through a $63.2 million public offering, extending its cash runway into the second half of 2028, while advancing its lead candidate EP-104GI with positive clinical data from the RESOLVE trial in eosinophilic esophagitis.
Key Financial Metrics
Actionable Insight
The financing provides substantial runway through 2028, reducing near-term dilution risk, but the sharply higher losses may concern investors. Upcoming clinical readouts from the RESOLVE trial could serve as key catalysts; traders should monitor for data releases and potential partnership interest.
Key Facts
- Net loss increased to $16.7M in Q4 2025 from $7.5M in Q4 2024 due to higher R&D and G&A expenses.
- Cash balance rose to $80.5M as of December 31, 2025, up from $33.1M in Q4 2024.
- Raised $63.2M gross proceeds from a public offering in February 2026, including issuance of common shares and pre-funded warrants.
- Positive 52-week follow-up and tissue health data from the ongoing RESOLVE trial for EP-104GI in eosinophilic esophagitis.
- Cash runway now extends into the second half of 2028, funded by existing cash and anticipated warrant exercises.
Financial Impact
Increased quarterly net loss by $9.2M YoY; cash position increased by $47.4M YoY to $80.5M; $63.2M raised in financing.
Risk Factors
- Increasing operating losses raise concerns about path to profitability.
- Clinical trial results may not translate into regulatory approval or commercial success.
- Dependence on third-party manufacturers and potential tariff impacts on U.S.-based production.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3255235 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 12, 2026
8d ago
|
Press Release
| $7.55 $6.29 | ▲ +16.69% | ▲ +15.53% | $6.96 (+7.81%) |
|
Apr 22, 2026
29d ago
|
6-K
| $7.06 $7.11 | ▲ +0.71% | ▲ +0.65% | $6.96 (−1.42%) |
|
Apr 21, 2026
4w ago
|
6-K
| $7.02 $7.11 | ▲ +1.28% | ▲ +0.20% | $6.96 (−0.85%) |
|
Apr 21, 2026
4w ago
|
Press Release
| $7.02 $7.11 | ▲ +1.28% | ▲ +0.20% | $6.96 (−0.85%) |
|
Mar 13, 2026
9w ago
|
Press Release
| $7.36 $7.10 | ▼ −3.53% | ▼ −1.41% | $6.96 (−5.43%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access